Lenacapavir
- Generic Name
- Lenacapavir
- Brand Names
- Sunlenca
- Drug Type
- Small Molecule
- Chemical Formula
- C39H32ClF10N7O5S2
- CAS Number
- 2189684-44-2
- Unique Ingredient Identifier
- A9A0O6FB4H
- Background
HIV/AIDS remains an area of concern despite the introduction of numerous successful therapies, mainly due to the emergence of multidrug resistance and patient difficulty in adhering to treatment regimens. Lenacapavir is a first-in-class capsid inhibitor that demonstrates picomolar HIV-1 inhibition as a monotherapy in vitro, little to no cross-resistance with existing antiretroviral agents, and extended pharmacokinetics with subcutaneous dosing.
Lenacapavir was first globally approved on August 22, 2022 by the European Commission to treat adults with multi-drug resistant HIV infection. On December 22, 2022, it was also approved by the FDA.
- Indication
Lenacapavir, in combination with other antiretroviral(s), is indicated for the treatment of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults who are experiencing a failure of their current antiretroviral regimen due to resistance, intolerance, or safety considerations.
- Associated Conditions
- Multidrug resistant HIV-1 infection
- Associated Therapies
- -
Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1
- First Posted Date
- 2024-08-01
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 75
- Registration Number
- NCT06532656
- Locations
- 🇺🇸
Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, United States
🇮🇹IRCCS Ospedale Pediatrico Bambino Gesu, UOS Infezioni Complesse e Perinatali, Roma, Italy
🇿🇦Be Part Yoluntu, Cape Town, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.